Clinical Trials Directory

Trials / Completed

CompletedNCT05829382

A Study of Biological Effects of a Polyphenol Supplement

A Randomized, Double-blind, Placebo Controlled, Cross-over Clinical Trial of Acute Safety and Biological Effects of a Polyphenol Supplement

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
30 (actual)
Sponsor
Helse Stavanger HF · Other Government
Sex
All
Age
55 Years – 80 Years
Healthy volunteers
Accepted

Summary

A randomized, double-blind, placebo controlled, cross-over trial to investigate the effect of the Investigational Product "DailyColors™" (DC) on age-related pathways in adults. The aim of this study is to measure the effects of acute treatment with DC on key pathways relevant to healthy ageing using blood biomarkers. Based on power calculations a sample size of 20, is sufficient to detect an effect size of 0.46 at a power \> 90%. To account for dropout the investigators will include 26 subjects in total.

Detailed description

Aims: The aim of this study is to measure the effects of acute treatment with DC on key pathways relevant to healthy ageing using blood biomarkers. Hypotheses: There will be preliminary evidence that the IP has positive clinical effects on biologically relevant pathways related to healthy aging of brain and muscle including blood markers of inflammation, oxidative stress markers, and trophic factors. Design: A randomized, double-blind, placebo controlled, cross-over trial to investigate the effect of the Investigational Product (DailyColors™) on age-related pathways in adults. Participants will receive DailyColors™ or placebo for a week, then one week wash-out, and then placebo/Dailycolors™ for a week, in random order. In addition, participants will be invited to participate in an open-label extension study for 3 months.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTDailyColors™Capsule containing active ingredient administred daily by the participant during the trial period
DIETARY_SUPPLEMENTPlaceboCapsule containing placebo administered daily by the participant during the trial period

Timeline

Start date
2023-03-15
Primary completion
2023-06-30
Completion
2023-06-30
First posted
2023-04-25
Last updated
2024-05-16

Locations

1 site across 1 country: Norway

Source: ClinicalTrials.gov record NCT05829382. Inclusion in this directory is not an endorsement.